Elephas launched elive, a platform designed to assess real immune behavior in live tumor biopsies beyond current predictive biomarkers.
Public source
Publisher name
Public post
Immunotherapy has transformed cancer care — yet translating immune biology into actionable drug development insights remains one of the field’s biggest challenges. That'…
Company
Elephas
Live tumor profiling for immunotherapy response prediction
- Industry
- Biotechnology Research
- Location
- Madison, US
- Company size
- 51–200 employees
About Elephas
Elephas has developed an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the elive™ platform enables a real-time characterization of immune response. To learn more, visit www.elephas.com
See moreLatest activity
Latest activity from Elephas
3 signals
Research & Knowledge
Elephas introduced an AI Avatar that quickly walks through the ASCO2026 poster showing 93% concordance between a cancer patient's clinical response on immunotherapy and the Functional Precision Medicine platform's predicted response.
Research & Knowledge
Elephas presented new data on the elive™ index, a classifier of ex vivo immune checkpoint inhibitor (ICI) response built from live tumor fragments at ASCO26.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
OncoOptima
OncoOptima launched OncoChoice, a drug activity test measuring how a patient's own cancer cells respond to specific treatments, reporting cell-activity data back to the ordering physician.
Products & Services
Alithea Bio
Alithea Bio introduced FindingNEO, a neoantigen prioritization pipeline that scores candidates against real immunopeptidomics evidence from HLA-Compass.
Products & Services
Northstar Oncology by BillionToOne
Northstar Oncology by BillionToOne launched Northstar Origin, an add-on to Northstar Select designed to predict tissue of origin directly from circulating tumor DNA (ctDNA) in 91% of cases.
Products & Services
Pheast Therapeutics
Pheast Therapeutics launched PHST001, a drug designed to restore immune recognition and hold FDA Fast Track Designation for patients with advanced platinum-resistant ovarian cancer.
Products & Services
Caris Life Sciences